<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378364</url>
  </required_header>
  <id_info>
    <org_study_id>1304.1</org_study_id>
    <secondary_id>2011-000713-39</secondary_id>
    <nct_id>NCT01378364</nct_id>
  </id_info>
  <brief_title>Phase I Study of AbGn-168H in Healthy Male Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics Study of Single Rising Doses of AbGn-168H Administered by Intravenous Infusion (125 μg/kg, 500 μg/kg, 1 mg/kg, 2 mg/kg) or Subcutaneous Injection (125 μg/kg, 1 mg/kg) to Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate safety, tolerability and pharmacokinetics of single
      rising doses of AbGn-168H administered by intravenous infusion or subcutaneous injection to
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be assessed in a descriptive way based on: Physical examination, vital sign, 12-lead ECG, clinical laboratory tests, adverse events, assessment of tolerability by investigator</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRT sc (mean residence time of the analyte in the body after subcutaneous injection)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL (total/apparent clearance of the analyte in plasma after intravascular administration)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in plasma after extravascular administration)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V z (apparent volume of distribution during the terminal phase delta z following an intravascular dose)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V z/F (apparent volume of distribution during the terminal phase delta z after extravascular administration)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V ss (apparent volume of distribution at steady state following intravascular administration)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t max (time from dosing to maximum measured concentration)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-tz: The area under the plasma concentration-time curve over the time interval from 0 to the last timepoint at which concentrations of AbGn-168H can be measured</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUC tz-infinity: The percentage of the AUC0-infinity obtained by extrapolation from the last evaluable timepoint</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta z (terminal rate constant in plasma)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t 1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT iv (mean residence time of the analyte in the body after intravenous injection or infusion)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AbGn-168H very low dose i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-168H low dose i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-168H medium dose i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-168H high dose i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-168H very low dose s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbGn-168H medium dose s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-168H</intervention_name>
    <description>single very low dose of AbGn-168H i.v.</description>
    <arm_group_label>AbGn-168H very low dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-168H</intervention_name>
    <description>single low dose of AbGn-168H i.v.</description>
    <arm_group_label>AbGn-168H low dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo i.v.</description>
    <arm_group_label>AbGn-168H very low dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo i.v.</description>
    <arm_group_label>AbGn-168H low dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo i.v.</description>
    <arm_group_label>AbGn-168H medium dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo i.v.</description>
    <arm_group_label>AbGn-168H high dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-168H</intervention_name>
    <description>single medium dose of AbGn-168H i.v.</description>
    <arm_group_label>AbGn-168H medium dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-168H</intervention_name>
    <description>single high dose of AbGn-168H i.v.</description>
    <arm_group_label>AbGn-168H high dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-168H</intervention_name>
    <description>single low dose of AbGn-168H s.c.</description>
    <arm_group_label>AbGn-168H very low dose s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo s.c.</description>
    <arm_group_label>AbGn-168H very low dose s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of Placebo s.c.</description>
    <arm_group_label>AbGn-168H medium dose s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn-168H</intervention_name>
    <description>single medium dose of AbGn-168H s.c.</description>
    <arm_group_label>AbGn-168H medium dose s.c.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure (BP), pulse rate (PR)) within normal range, 12-lead electrocardiogram
             (ECG), clinical laboratory tests

          2. Body Mass Index (BMI) between 18.5 and 29.9 kg/m2

          3. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease in the opinion of the
             investigator

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological and hormonal disorders

          4. Chronic or relevant acute infections including hepatitis and tuberculosis, or a
             positive PPD skin test (5 mm or greater) at screening or within the previous 3 months

          5. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          6. Use of biologic agents within 12 weeks prior to treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1304.1.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

